Predicting outcomes of prostate cancer immunotherapy by personalized mathematical models

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Kronik, Natalie ^a,c   Kogan, Yuri ^a   Elishmereni, Moran ^a   Halevi Tobias, Karin ^a   Vuk Pavlović, Stanimir ^b   Agur, Zvia ^a  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b MAYO CLINIC   (United States)

^c HOLON INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR CELL VACCINE; CANCER VACCINE;

ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CELL INTERACTION; CLINICAL TRIAL; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG SPECIFICITY; HUMAN; IMMUNE SYSTEM; INTERMETHOD COMPARISON; MALE; MATHEMATICAL MODEL; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TUMOR VOLUME; VALIDATION STUDY; ALGORITHM; CALIBRATION; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; ONCOLOGY; PERSONALIZED MEDICINE; PROSTATE; PROSTATE TUMOR; THEORETICAL MODEL; TREATMENT OUTCOME;

ALGORITHMS; CALIBRATION; CANCER VACCINES; HUMANS; IMMUNOTHERAPY; INDIVIDUALIZED MEDICINE; MALE; MEDICAL ONCOLOGY; MODELS, THEORETICAL; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78650111045     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015482     Document Type: Article

References (59)

1. Damber JE, Aus G (2008) Prostate cancer. Lancet 371: 1710-1721.
2. Machiels JP, Mazzeo F, Clausse M, Filleul B, Marcelis L, Honhon B, et al. (2008) Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J Clin Oncol 26: 5261-5268.
3. Kiessling A, Fussel S, Wehner R, Bachmann M, Wirth MP, et al. (2008) Advances in specific immunotherapy for prostate cancer. Eur Urol 53: 694- 708.
4. Marrari A, Iero M, Pilla L, Villa S, Salvioni R, et al. (2007) Vaccination therapy in prostate cancer. Cancer Immunol Immunother 56: 429-445.
5. Harzstark AL, Small EJ (2009) Immunotherapeutics in development for prostate cancer. Oncologist 14: 391-398.
6. Schellhammer PF, Higano C, Berger ER, Shore N, Small E, et al. (2009) A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). ChicagoIllinois: in Annual Meeting of the American Urological Association. pp April 25-30, 2009.
7. Brill TH, Kubler HR, Pohla H, Buchner A, Fend F, et al. (2009) Therapeutic vaccination with an IL-2-IFNc-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer-a phase I/II trial. Hum Gene Ther 20: 1641-1651.
8. Olson WC, Heston WD, Rajasekaran AK (2007) Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev Recent Clin Trials 2: 182-190.
9. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115: 3670-3679.
10. Michael A, Ball G, Quatan N, Wushishi F, Russell N, et al. (2005) Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 11: 4469-4478.
11. Weiner LM (2008) Cancer immunotherapy-the endgame begins. N Engl J Med 358: 2664-2665.
12. Aalamian-Matheis M, Chatta GS, Shurin MR, Huland E, Huland H, et al. (2007) Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA. Adv Exp Med Biol 601: 173-182.
13. Brandacher G, Winkler C, Schroecksnadel K, Margreiter R, Fuchs D (2006) Antitumoral activity of interferon-c involved in impaired immune function in cancer patients. Curr Drug Metab 7: 599-612.
14. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
15. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, et al. (1998) Impaired expression and function of signal-transducing f chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 32: 109-119.
16. Pawelec G (2004) Immunotherapy and immunoselection-tumour escape as the final hurdle. FEBS Lett 567: 63-66.
17. Vuk-Pavlović S (2008) Rebuilding immunity in cancer patients. Blood Cells Mol Disease 40: 90-100.
18. Bajzer Ž, Pavelić K, Vuk-Pavlović S (1984) Growth self-incitement in murine melanoma B16: a phenomenological model. Science 225: 930-932.
19. Bajzer Ž, Vuk-Pavlović S (1990) Quantitative aspects of autocrine regulation in tumors. Crit Rev Oncog 2: 53-73.
20. Bajzer Ž, Vuk-Pavlović S (2005) Modeling positive regulatory feedbacks in cellcell interactions. Biosystems 80: 1-10.
21. Swanson KR, Bridge C, Murray JD, Alvord EC, Jr. (2003) Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 216: 1-10.
22. Agur Z, Arakelyan L, Daugulis P, Ginosar Y (2004) Hopf point analysis for angiogenesis models. Discrete and Continuous Dynamical Systems 4B: 29-38.
23. Arakelyan L, Merbl Y, Agur Z (2005) Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. Eur J Cancer 41: 159-167.
24. Arakelyan L, Vainstein V, Agur Z (2002) A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 5: 203-214.
25. Gorelik B, Ziv I, Shohat R, Wick M, Hankins WD, et al. (2008) Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Res 68: 9033-9040.
26. Goldie JH, Coldman AJ (1979) A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727-1733.
27. Harnevo LE, Agur Z (1992) Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency. Cancer Chemother Pharmacol 30: 469-476.
28. Acharya RS, Sundareshan MK (1984) Development of optimal drug administration strategies for cancer-chemotherapy in the framework of systems theory. Int J Biomed Comput 15: 139-150.
29. Agur Z, Arnon R, Schechter B (1992) Effect of the dosing interval on myelotoxicity and survival in mice treated by cytarabine. Eur J Cancer 28A: 1085-1090.
30. Agur Z, Dvir Y (1994) Use of knowledge on {Qn} series for predicting optimal chemotherapy treatment. Rand Comp Dynamics 2: 279-286.
31. Agur Z, Hassin R, Lavi O (2006) Optimizing chemotherapy scheduling using local search heuristics. Operations Res 54: 829-846.
32. Cojocaru L, Agur Z (1992) A theoretical analysis of interval drug dosing for cellcycle- phase-specific drugs. Math Biosci 109: 85-97.
33. Younga D, Ramanujana S, Shodaa LKM (2009) Chapter 15: Applications of immunologic modeling to drug discovery and development. In: Liu E, Lauffenburger DA, eds. Systems Biomedicine concepts and perpectives. Foster City: Elsevier.
34. Bunimovich-Mendrazitsky S, Byrne H, Stone L (2008) Mathematical model of pulsed immunotherapy for superficial bladder cancer. Bull Math Biol 70: 2055-2076.
35. Cappuccio A, Elishmereni M, Agur Z (2006) Cancer immunotherapy by interleukin-21: potential treatment strategies evaluated in a mathematical model. Cancer Res 66: 7293-7300.
36. Cappuccio A, Elishmereni M, Agur Z (2007) Optimization of interleukin-21 immunotherapeutic strategies. J Theor Biol 24: 259-266.
37. de Pillis LG, Gu W, Radunskaya AE (1006) Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. J Theor Biol 238: 841-862.
38. de Pillis LG, Radunskaya A (2001) A mathematical tumor model with immune resistance and drug therapy: an optimal control approach. Computational and Mathematical Methods in Medicine 3: 1748-6718.
39. de Pillis LG, Radunskaya AE, Wiseman CL (2005) A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Res 65: 7950-7958.
40. Kirschner D, Panetta JC (1998) Modeling immunotherapy of the tumor-immune interaction. J Math Biol 37: 235-252.
41. Kronik N, Kogan Y, Vainstein V, Agur Z (2008) Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics. Cancer Immunol Immunother 57: 425-439.
42. 4+T cells impinge on tumor immunobiology: the differential response of tumors to therapies. J Immunol 179: 5659-5668.
43. Louzoun Y (2007) The evolution of mathematical immunology. Immunol Rev 216: 9-20.
44. Nani F, Freedman HI (2000) A mathematical model of cancer treatment by immunotherapy. Math Biosci 163: 159-199.
45. Elishmereni M, Kheifetz Y, Inbar O, Sondergaard H, Thygesen P, et al. (2008) IL-21 immunotherapy in solid cancers: Therapeutic insights froma preclinically validated pharmacokinetic and pharmacodynamic model. In: AACR International Conference "Advances in Cancer Research - From Laboratory to the Clinic" Dead Sea, Jordan.
46. Collins C, Carducci MA, Eisenberger MA, Isaacs JT, Partin AW, et al. (2007) Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther 6: 1360-1367.
47. Willimsky G, Czeh M, Loddenkemper C, Gellermann J, Schmidt K, et al. (2008) Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med 205: 687-1700.
48. Kulprathipanja NV, Kruse CA (2004) Microglia phagocytose alloreactive CTLdamaged 9L gliosarcoma cells. J Neuroimmunol 153: 76-82.
49. De Vleeschouwer S, Arredouani M, Ade M, Cadot P, Vermassen E, et al. (2005) Uptake and presentation of malignant glioma tumor cell lysates by monocytederived dendritic cells. Cancer Immunol Immunother 54: 372-382.
50. Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, et al. (2004) Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 18: 1810-1815.
51. Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, et al. (2003) Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 17: 894-899.
52. Martin-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, et al. (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med. 198: 615-621.
53. Langenkamp A, Messi M, Lanzavecchia A, Sallusto F (2000) Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol 1: 311-316.
54. Chen M, Huang L, Shabier Z, Wang J (2007) Regulation of the lifespan in dendritic cell subsets. Mol Immunol 44: 2558-2565.
55. Min WP, Zhou D, Ichim TE, Strejan GH, Xia X, et al. (2003) Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 170: 1304-1312.
56. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, et al. (2006) Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 116: 2423-2433.
57. George TC, Bilsborough J, Viney JL, Norment AM (2003) High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol 33: 502-511.
58. 8+ cytotoxic T-lymphocytes in vitro using antigenpresenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36: 129-138.
59. Street D, Kaufmann AM, Vaughan A, Fisher SG, Hunter M, et al. (1997) Interferon-c enhances susceptibility of cervical cancer cells to lysis by tumorspecific cytotoxic T cells. Gynecol Oncol 65: 265-272.